PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: oncgnostics

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

oncgnostics and Greiner Bio-One Diagnostics Sign Partnership Agreement - The oncgnostics GmbH has taken on board the international firm Greiner Bio-One GmbH as a sales and marketing partner for its new screening test for cervical cancer
oncgnostics and Greiner Bio-One Diagnostics Sign Partnership Agreement


NewswireToday - /newswire/ - Jena, Thuringia, Germany, 2015/11/18 - The oncgnostics GmbH has taken on board the international firm Greiner Bio-One GmbH as a sales and marketing partner for its new screening test for cervical cancer.

Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


The oncgnostics GmbH has taken on board the international firm Greiner Bio-One GmbH as a sales and marketing partner for its new screening test for cervical cancer. With CE approval issued for GynTect® in October of this year, the test is now approved for use in laboratories throughout Europe. The test is also expected to be certified for additional markets, for example in the USA.

Oncgnostics was founded in 2012 as a spinoff from the Department of Gynecology at the University of Jena with the aim of developing highly reliable biomolecular tests for cancer diagnostics based on patented epigenetic markers. At the beginning of October, GynTect became the first new diagnostic follow-up test developed by oncgnostics GmbH to obtain the CE-IVD label for the EU and other nations.

Rapid and reliable results

In developing GynTect, oncgnostics created a biomolecular test that provides early clarification of whether a cervical disease with the potential to proceed to cancer is actually present or developing in a woman with an abnormal Pap smear or documented human papillomavirus (HPV) infection. The test returns rapid and reliable results, thereby permitting rapid and reliable identification of those women with diseases requiring therapy. The availability of this test significantly improves risk assessment in cervical cancer screening: it helps to prevent unnecessary and premature surgery while increasing the chances of early and successful therapeutic intervention.

Distribution by an expert and established partner

To facilitate distribution of the test on the international market, oncgnostics will collaborate with Greiner Bio-One GmbH, starting immediately. The firm is already well known to many laboratories as a supplier and partner and has a long-standing presence in the field of early cervical cancer detection with its own HPV test PapilloCheck®. As a follow-up diagnostic test for women who have tested positive for HPV, GynTect will also serve as a follow-up test for PapilloCheck®. Further, in view of the pending new 2016 guidelines for cervical cancer screening in Germany and in other countries, which approve HPV testing as a primary screening option, the HPV testing market is becoming highly competitive. “With GynTect, we can further strengthen and expand our position in the diagnostic testing field. oncgnostics has precisely the right product to do this,” explains Dr. Ron Opstelten, Managing Director at Greiner Bio-One Diagnostics GmbH. In addition to Germany, the test is also marketed through Greiner Bio-One Diagnostics GmbH in Austria, Switzerland, France, England, and the BeNeLux countries.

World premiere for an international audience at the MEDICA 2015 Trade Fair

From 16th to 19th November, oncgnostics will be represented by an expert team at Booth G22 in Hall 15 at the MEDICA Trade Fair. On this occasion, GynTect will be presented to a large professional audience for the first time. The representatives who will be onsite and conducting press interviews are the two Managing Directors, Dr. Martina Schmitz and Dr. Alfred Hansel.

About Greiner Bio-One GmbH
Greiner Bio-One specializes in the development, production and distribution of high-quality products for the laboratory market made from synthetic materials. The firm is a technology partner for hospitals, laboratories, universities, research institutes, the diagnostic products and pharmaceutical industry, and biotechnology. Greiner Bio-One is divided into four lines of business: Pre-analytics, BioScience, Diagnostics, and OEM. The Greiner Bio-One Diagnostics Division develops, produces and markets products for human diagnostics, biopharmaceutical production, the food sector, and OEM products for the specialty areas of dental and veterinary medicine. Its two product families “oCHeck” and “Genspeed” meet the requirements for mass analyses (high throughput) as well as for individual analyses in acute diagnostics. Its test procedures are used to monitor vaccine safety and to detect sexually transmitted diseases and hospital pathogens, among others. In addition to its head office in Rainbach (Austria), the company’s sales and marketing headquarters are located in Frickenhausen (Germany).

About oncgnostics GmbH:
oncgnostics GmbH is a spin-off from the university women’s hospital Jena and was founded early in 2012. As a molecular diagnostic company oncgnostics is specialized on cancer diagnostics. Oncgnostics tests target epigenetic changes, so-called DNA methylations, that typically occur in cancer cells. The patented biomarkers which are evaluated using a specific algorithm are the core of the products and provide thus the basis for the company’s activities. Prominent investors have already invested into the market potential of the biotech startup, thus enabling the spin-off of the company and the development of the first product (High-Tech-Gründerfonds, Stiftung für Technologie, Innovation und Forschung Thüringen, bm-t Beteiligungsmanagement Thüringen GmbH and further investors).

Further information concerning cervical cancer screening:
Currently, cervical cancer screening is mainly performed by examining a smear from the portio and cervix uteri by microscopy (Pap smear). This Pap smear shows if cellular changes are present in the material. Testing for HPV shows if a patient is infected with high-risk human papillomavirus (HPV). But only a small number of HPV infections may lead to cervical cancer. In Germany, ca 90,000 so-called conizations, during which cervical tissue is removed by surgery are performed annually, based on Pap smear and further examination results with almost half of these surgeries being unnecessary. Exact triage tests are required in order to determine if a precancerous lesion or even cancer demanding treatment is present in case of an abnormal Pap smear. GynTect® may simplify these processes for gynaecologists and patients drastically. With unequivocal results GynTect® leads to a fast and reliable identification of women with a disease requiring therapy.

oncgnostics GmbH
Dr. Alfred Hansel (CEO)
Winzerlaer Str. 2 - 07745 Jena (Germany)
P: +49 3641 508456

Media Agency
Tower PR
Leutragraben 1
07743 Jena
P: +49 3641 87611-80 / E: oncgnostics[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: oncgnostics


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!

oncgnostics and Greiner Bio-One Diagnostics Sign Partnership Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Martina Schmitz - 
+49(3641) 87611-83 pr[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any oncgnostics securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From oncgnostics / Company Profile

Read Medical Services/Equipment Most Recent Related Newswires:

ZOLL Canada Wins Tender to Equip Province of Québec Paramedic Services with ZOLL X Series Monitor/Defibrillators
Top Speakers, Brands Commit to SCBIO 2017 - SC Governor McMaster to Keynote Life Sciences Conference
Frost & Sullivan Recognizes Acelity as a Leader in the Field with its New V.A.C.ULTA™ 4 Therapy System and V.A.C. VERAFLO CLEANSE CHOICE™ Dressing
Frost & Sullivan Recognizes Ventec Life Systems for New Product Innovation - Game-changing, Modular Respiratory System, VOCSN
BD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis
GE Healthcare Advances the Delivery of Cell Therapies with New Thawing Technology
Ansell Limited Announces the Closing of the Sale of its Sexual Wellness Business
PQ Bypass Earns Frost & Sullivan’s European Technology Innovation Award for its Proprietary DETOUR System for Percutaneous Bypass
Curaçao EMS Uses ZOLL Autopulse to Save Tourist in Sudden Cardiac Arrest
ZOLL to Showcase Expanded Portfolio of AEDs at Caravan Salon 2017
MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®
MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test
Datalogic Announces New Healthcare Memor X3 HC Mobile Computer
Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  RightITnow Ltd


  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (